In Re: lorazepam/cloraze v. Mylan Laboratories

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA

IN RE LORAZEPAM & CLORAZEPAT E ) MDL Docket No. 1290 (TFH/JMF) ANTITRUST LITIG. ) Misc. No. 99-276 (TFH) ) ) HEALTH CARE SERV. CORP., ) Plaintiff, ) ) v. ) Civ. No. 01-2646 (TFH) ) MYLAN LABS., INC., et al., ) Defendants. ) ) ) BLUE CROSS BLUE SHIELD OF MINN., ) BLUE CROSS BLUE SHIELD OF MASS., ) and FEDERATED MUT. INS. CO. ) Plaintiffs, ) ) v. ) Civ. No. 02-1299 (TFH) ) MYLAN LABS., INC., et al., ) Defendants. ) _______________________________________)

ORDER

Pending before the Court are (1) Plaintiffs’ Joint Motion for Leave to File Amended

Complaints [ECF. No. 1049], and (2) Plaintiffs’ Joint Motion to Dismiss Claims and for Order for

Remittitur [ECF No. 1051]. This Court will not rule on Plaintiffs’ request for a remittitur at this time.

However, with respect to the remainder of the motions, it is now

ORDERED, that Plaintiffs’ Joint Motion for Leave to File Amended Complaints is

GRANTED, and it is further ORDERED, Plaintiffs’ Joint Motion to Dismiss Claims and for Order for Remittitur is

GRANTED IN PART, and it is further

ORDERED, that pursuant to Rule 21 of the Federal Rules of Civil Procedure, the claims of

the 775 self-funded customers listed in the Declaration of Justin McLean and the corresponding

Exhibits [ECF No. 1051-4] are DISMISSED WITHOUT PREJUDICE

SO ORDERED.

July 29, 2014 __________________________ Thomas F. Hogan UNITED STATES DISTRICT JUDGE

-2-